Sarcoma & GIST
News from the FDA/CDC
FDA grants accelerated approval to olaratumab for soft tissue sarcoma
Olaratumab, a platelet-derived growth factor receptor-alpha blocking antibody, is the first new therapy approved in 40 years for the initial...
Conference Coverage
Yes, neoadjuvant chemo improves survival in soft tissue sarcomas
Interim results from a randomized trial show that combination chemotherapy with an anthracycline and an alkylating agent offers both a relapse-...
Conference Coverage
Database review supports chemoradiation for high-risk sarcomas
Neoadjuvant chemotherapy and radiation appear to offer long-term benefits in patients with high-risk soft tissue sarcomas of the extremities.
News
Palifosfamide plus doxorubicin does not improve survival in sarcoma
Key clinical point: Palifosfamide combined with doxorubicin did not improve survival in metastatic soft tissue sarcoma. Major finding: The median...
News
FDG-PET gives early indication of response to therapy for Ewing sarcoma
Key clinical point: FDG-PET predicted response to Ewing sarcoma therapy significantly earlier than MRI or CT. Major finding: Day 9 FDG-PET scans...
News
Changes in HIV-related cancers reflect changes in HIV patient care
Key clinical point: Kaposi’s sarcoma and non-Hodgkin lymphoma are appearing in older, less- immunosuppressed patients. Major finding: From 1996-...
News
Second malignancy risk higher in patients with fusion-negative sarcoma
Community Translations
Trabectedin expands treatment options for some forms of advanced soft tissue sarcoma
Article
Mining for information, participation in clinical trials
News
No benefit from added trabectedin for STS patients
Key clinical point: When trabectedin was administered to soft tissue sarcoma (STS) patients receiving doxorubicin, neither progression-free nor...